US court orders Guardant Health to pay $245 million for cancer patent infringement
A federal judge ordered Guardant Health to pay over $245 million to TwinStrand Biosciences and the University of Washington for patent infringement. The ruling follows a jury verdict regarding patented DNA sequencing technology, requiring Guardant to pay an upfront sum and ongoing royalties until March 2033. The company plans to appeal the judgment, asserting confidence in its position.